RCS - Creo Medical Group - Presentation at Growth and Innovation Forum 2022

Creo MedicalAnnouncement

07/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220207:nRSG8159Aa&default-theme=true

RNS Number : 8159A  Creo Medical Group PLC  07 February 2022

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Presentation at Growth and Innovation Forum 2022

 

Patient testimonials following SSD procedures to feature in management's
presentation

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of surgical endoscopy, announces that it will be presenting at
the virtual Growth and Innovation Forum 2022 on Tuesday 8 February, to be
hosted by Cenkos in partnership with Proactive, and sponsored by PrimaryBid.

 

This is a one-day investor event exhibiting companies focused on growth and
technology, attracting both institutional and retail investors. Creo's
management team will be presenting at 13:00 GMT. To register for the afternoon
session, click here (https://event.webinarjam.com/register/1388/pyy7gsmog) .
The slides will be made available on the Company website shortly after the
event.

 

For further information on the event, please visit the website here
(https://www.proactiveinvestors.co.uk/register/event_details/376) .

 

No new material information will be disclosed at the event, but will include
testimonials from patients who have recently undergone procedures using Creo's
flagship Speedboat® Inject device.

Commenting on the recent removal of a 10cm lesion via a Speedboat Submucosal
Dissection (SSD)
(https://creomedical.com/wp-content/uploads/2021/08/SSD-Brochure-ROW-v4.pdf) ,
the patient  described the after-effects of the SSD procedure as being
"negligible, manageable to the extent to it being a non-event.

"I still couldn't square how much work was done for how little I felt that
work had been done…I just feel that I'm back to normal, completely."

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

Enquiries:

 

 Creo Medical Group plc                              www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                  +44 (0)1291 606 005

 Cenkos Securities plc                               +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Sales)

 Numis Securities Limited (Joint Broker)             +44 (0)20 7260 1000

 Freddie Barnfield / James Black / Duncan Monteith

 Walbrook PR Ltd                                     Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGGGDDBXGDGDR